Operaciones Anixa Biosciences, Inc. - ANIX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.23 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 2.97 |
| Abrir* | 2.94 |
| Cambio de 1 año* | -1.67% |
| Rango del día* | 2.9 - 3.04 |
| Rango de 52 semanas | 2.50-6.25 |
| Volumen medio (10 días) | 64.75K |
| Volumen medio (3 meses) | 1.10M |
| Capitalización de mercado | 143.18M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 30.92M |
| Ingresos | N/A |
| EPS | -0.40 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.96 |
| Próxima fecha de resultados | N/A |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 2.99 | 0.05 | 1.70% | 2.94 | 3.08 | 2.90 |
| Jun 28, 2022 | 2.97 | -0.04 | -1.33% | 3.01 | 3.14 | 2.95 |
| Jun 27, 2022 | 3.16 | 0.15 | 4.98% | 3.01 | 3.19 | 3.01 |
| Jun 24, 2022 | 3.04 | 0.07 | 2.36% | 2.97 | 3.12 | 2.97 |
| Jun 23, 2022 | 3.13 | 0.11 | 3.64% | 3.02 | 3.19 | 3.02 |
| Jun 22, 2022 | 3.18 | 0.21 | 7.07% | 2.97 | 3.18 | 2.97 |
| Jun 21, 2022 | 3.08 | 0.06 | 1.99% | 3.02 | 3.19 | 3.02 |
| Jun 17, 2022 | 3.00 | -0.16 | -5.06% | 3.16 | 3.16 | 2.96 |
| Jun 16, 2022 | 3.10 | 0.15 | 5.08% | 2.95 | 3.18 | 2.90 |
| Jun 15, 2022 | 3.08 | 0.29 | 10.39% | 2.79 | 3.15 | 2.79 |
| Jun 14, 2022 | 2.88 | -0.18 | -5.88% | 3.06 | 3.09 | 2.82 |
| Jun 13, 2022 | 3.07 | -0.18 | -5.54% | 3.25 | 3.31 | 3.04 |
| Jun 10, 2022 | 3.33 | -0.10 | -2.92% | 3.43 | 3.48 | 3.27 |
| Jun 9, 2022 | 3.48 | 0.07 | 2.05% | 3.41 | 3.68 | 3.41 |
| Jun 8, 2022 | 3.50 | 0.23 | 7.03% | 3.27 | 3.54 | 3.27 |
| Jun 7, 2022 | 3.38 | -0.49 | -12.66% | 3.87 | 3.91 | 3.30 |
| Jun 6, 2022 | 3.92 | -0.27 | -6.44% | 4.19 | 4.44 | 3.87 |
| Jun 3, 2022 | 3.94 | 0.16 | 4.23% | 3.78 | 3.96 | 3.61 |
| Jun 2, 2022 | 3.81 | 0.01 | 0.26% | 3.80 | 3.85 | 3.74 |
| Jun 1, 2022 | 3.69 | 0.18 | 5.13% | 3.51 | 3.70 | 3.37 |
Anixa Biosciences, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0.5125 | 0 | 0.25 | 1.1125 |
| Ingresos | 0 | 0.5125 | 0 | 0.25 | 1.1125 |
| Gastos totales de explotación | 13.875 | 13.6482 | 9.9782 | 12.14 | 15.4016 |
| Gastos de venta/general/administración Gastos, total | 7.172 | 7.0735 | 5.597 | 5.66283 | 6.91183 |
| Investigación y desarrollo | 6.703 | 6.18969 | 4.38121 | 5.47343 | 6.81304 |
| Depreciation / Amortization | 0 | 0.41875 | 0.3253 | ||
| Gastos (ingresos) extraordinarios | 0 | 0.385 | 0 | 0.585 | 1.35139 |
| Other Operating Expenses, Total | |||||
| Ingresos de explotación | -13.875 | -13.1357 | -9.9782 | -11.89 | -14.2891 |
| Ingresos por intereses (gastos), netos No operativos | 0.104 | 0.00232 | 0.03392 | 0.07135 | 0.04597 |
| Ingresos netos antes de impuestos | -13.771 | -13.1279 | -10.0924 | -11.8187 | -14.2431 |
| Ingresos netos después de impuestos | -13.771 | -13.1279 | -10.0924 | -11.8187 | -14.2431 |
| Beneficio neto antes de partidas extra. Elementos | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Ingresos netos | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Beneficio neto diluido | -13.595 | -12.9544 | -10.0184 | -11.647 | -13.996 |
| Promedio ponderado de acciones diluidas | 30.374 | 28.5789 | 22.229 | 19.7898 | 17.6243 |
| BPA diluido sin partidas extraordinarias | -0.44759 | -0.45329 | -0.45069 | -0.58854 | -0.79413 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA normalizado diluido | -0.44759 | -0.44 | -0.44403 | -0.55898 | -0.71745 |
| Total Adjustments to Net Income | 0 | ||||
| Intereses menores | 0.176 | 0.17352 | 0.07401 | 0.1716 | 0.24706 |
| Gain (Loss) on Sale of Assets | 0 | 0.00545 | -0.14808 |
| Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | Oct 2021 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Ingresos | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 3.609 | 2.797 | 3.589 | 3.88 | 4.07704 |
| Gastos de venta/general/administración Gastos, total | 1.924 | 1.352 | 1.854 | 2.042 | 1.9038 |
| Investigación y desarrollo | 1.685 | 1.445 | 1.735 | 1.838 | 2.17324 |
| Gastos (ingresos) extraordinarios | 0 | 0 | 0 | 0 | 0 |
| Ingresos de explotación | -3.609 | -2.797 | -3.589 | -3.88 | -4.07704 |
| Ingresos por intereses (gastos), netos No operativos | 0.08 | 0.022 | 0.001 | 0.001 | 0.00055 |
| Ingresos netos antes de impuestos | -3.529 | -2.775 | -3.588 | -3.879 | -4.07105 |
| Ingresos netos después de impuestos | -3.529 | -2.775 | -3.588 | -3.879 | -4.07105 |
| Intereses menores | 0.053 | 0.029 | 0.044 | 0.05 | 0.05778 |
| Beneficio neto antes de partidas extra. Elementos | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Ingresos netos | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Beneficio neto diluido | -3.476 | -2.746 | -3.544 | -3.829 | -4.01327 |
| Promedio ponderado de acciones diluidas | 30.764 | 30.451 | 30.152 | 30.125 | 30.0451 |
| BPA diluido sin partidas extraordinarias | -0.11299 | -0.09018 | -0.11754 | -0.1271 | -0.13357 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| BPA normalizado diluido | -0.11299 | -0.09018 | -0.11754 | -0.1271 | -0.13376 |
| Gain (Loss) on Sale of Assets | 0 | 0.00545 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 36.0034 | 9.36862 | 6.09312 | 5.53837 | 7.01394 |
| Efectivo e inversiones a corto plazo | 35.7279 | 9.05706 | 5.84163 | 5.05589 | 6.83937 |
| Efectivo y Equivalentes | 29.1283 | 6.41706 | 3.49163 | 3.05589 | 3.33937 |
| Inversiones a corto plazo | 6.5996 | 2.64 | 2.35 | 2 | 3.5 |
| Prepaid Expenses | 0.27556 | 0.30933 | 0.18497 | 0.17549 | 0.17457 |
| Total Assets | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Property/Plant/Equipment, Total - Net | 0.25396 | 0.05434 | 0.20057 | 0.07267 | 0.0527 |
| Property/Plant/Equipment, Total - Gross | 0 | 0.29558 | 0.12647 | 0.08843 | |
| Accumulated Depreciation, Total | 0 | -0.09502 | -0.0538 | -0.03573 | |
| Intangibles, Net | 0 | 0.8375 | 1.74578 | ||
| Total Current Liabilities | 1.27053 | 1.18859 | 1.48132 | 1.26511 | 0.88949 |
| Accounts Payable | 0.1362 | 0.23237 | 0.58582 | 0.58201 | 0.48032 |
| Accrued Expenses | 1.13433 | 0.95622 | 0.8955 | 0.6831 | 0.40917 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 0.8201 | 0.69161 | 1.05834 | 1.01373 | 0.88949 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.22008 | 0 | |||
| Total Equity | 35.4373 | 8.76136 | 5.23535 | 5.43481 | 7.92292 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.30051 | 0.24249 | 0.20332 | 0.18909 | 0.16603 |
| Additional Paid-In Capital | 239.927 | 200.354 | 186.849 | 175.416 | 163.931 |
| Retained Earnings (Accumulated Deficit) | -204.79 | -191.836 | -181.817 | -170.17 | -156.174 |
| Total Liabilities & Shareholders’ Equity | 36.2574 | 9.45296 | 6.29369 | 6.44854 | 8.81242 |
| Total Common Shares Outstanding | 30.0509 | 24.2487 | 20.3318 | 18.9086 | 16.6028 |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
| Total deudores, neto | 0.00223 | 0.06653 | 0.30699 | ||
| Accounts Receivable - Trade, Net | 0.00223 | 0.06653 | 0.30699 | ||
| Minority Interest | -0.67051 | -0.49698 | -0.42298 | -0.25138 | |
| Other Long Term Assets, Total | 0 | 0.03 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 32.563 | 34.994 | 36.0034 | 37.052 | 38.472 |
| Efectivo e inversiones a corto plazo | 32.231 | 34.53 | 35.7279 | 36.622 | 38.1027 |
| Efectivo y Equivalentes | 27.732 | 29.781 | 29.1283 | 27.2222 | 27.7034 |
| Inversiones a corto plazo | 4.499 | 4.749 | 6.5996 | 9.39978 | 10.3993 |
| Prepaid Expenses | 0.332 | 0.464 | 0.27556 | 0.43001 | 0.36921 |
| Total Assets | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Property/Plant/Equipment, Total - Net | 0.234 | 0.244 | 0.25396 | 0.01041 | 0.02557 |
| Other Long Term Assets, Total | 0 | 0 | 0 | ||
| Total Current Liabilities | 1.189 | 1.787 | 1.27053 | 1.20802 | 1.44287 |
| Accounts Payable | 0.093 | 0.504 | 0.1362 | 0.20773 | 0.43801 |
| Accrued Expenses | 1.096 | 1.283 | 1.13433 | 1.00029 | 1.00486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.626 | 1.275 | 0.8201 | 0.5953 | 0.88376 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -0.765 | -0.721 | -0.67051 | -0.61273 | -0.55911 |
| Total Equity | 32.171 | 33.963 | 35.4373 | 36.4671 | 37.6138 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.302 | 0.301 | 0.30051 | 0.2995 | 0.3145 |
| Additional Paid-In Capital | 244.032 | 242.281 | 239.927 | 236.944 | 233.742 |
| Retained Earnings (Accumulated Deficit) | -212.163 | -208.619 | -204.79 | -200.777 | -196.443 |
| Total Liabilities & Shareholders’ Equity | 32.797 | 35.238 | 36.2574 | 37.0624 | 38.4975 |
| Total Common Shares Outstanding | 30.1547 | 30.1323 | 30.0509 | 29.9499 | 31.4499 |
| Other Liabilities, Total | 0.202 | 0.209 | 0.22008 | ||
| Total Preferred Shares Outstanding | 0 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -13.1279 | -10.0924 | -11.8187 | -14.2431 | -5.00899 |
| Efectivo de actividades de explotación | -4.93688 | -6.17567 | -4.74143 | -4.2734 | -3.79671 |
| Efectivo de actividades de explotación | 0 | 0.03828 | 0.04756 | 0.01844 | 0.04322 |
| Amortization | 0 | 0.41875 | 0.3253 | 0.3253 | |
| Partidas no monetarias | 8.1125 | 4.33743 | 6.1325 | 9.55825 | 0.43553 |
| Cambios en el capital circulante | 0.07855 | -0.45901 | 0.47842 | 0.0677 | 0.40824 |
| Efectivo de actividades de inversión | -3.91768 | -0.30579 | -0.52546 | 1.4616 | -2.73519 |
| Gastos de capital | 0 | -0.01579 | -0.17546 | -0.0384 | -0.03019 |
| Otras partidas de flujo de caja de inversión, total | -3.91768 | -0.29 | -0.35 | 1.5 | -2.705 |
| Efectivo procedente de actividades de financiación | 31.5658 | 9.4069 | 5.70262 | 2.52832 | 7.38295 |
| Elementos de flujo de caja de financiación | 0.01403 | 0 | |||
| Emisión (retiro) de acciones, neto | 31.5658 | 9.4069 | 5.68858 | 2.52832 | 10.3829 |
| Variación neta de la tesorería | 22.7112 | 2.92544 | 0.43574 | -0.28348 | 0.85105 |
| Intereses pagados en efectivo | 0.00182 | 0.03989 | 0 | 0.27243 | |
| Emisión (amortización) de deuda, neta | 0 | -3 |
| Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.467 | -3.879 | -13.1279 | -9.05688 | -4.66927 |
| Cash From Operating Activities | -3.503 | -1.197 | -4.93688 | -3.89271 | -2.41195 |
| Cash From Operating Activities | 0 | 0 | 0 | ||
| Non-Cash Items | 4.12 | 2.364 | 8.1125 | 5.26318 | 2.06069 |
| Cash Interest Paid | 2 | 1 | 0.00182 | 0.00168 | 0.0014 |
| Changes in Working Capital | -0.156 | 0.318 | 0.07855 | -0.09901 | 0.19663 |
| Cash From Investing Activities | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Capital Expenditures | 0 | 0 | 0 | ||
| Other Investing Cash Flow Items, Total | 2.1 | 1.85 | -3.91768 | -6.72434 | -7.72385 |
| Cash From Financing Activities | 0.007 | 0 | 31.5658 | 31.4222 | 31.4222 |
| Financing Cash Flow Items | 0 | -2.54893 | -2.54893 | ||
| Issuance (Retirement) of Stock, Net | 0.007 | 0 | 31.5658 | 33.9711 | 33.9711 |
| Net Change in Cash | -1.396 | 0.653 | 22.7112 | 20.8051 | 21.2864 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.2268 | 1307142 | 7144 | 2022-12-31 | LOW |
| Titterton (Lewis H Jr) | Individual Investor | 2.5031 | 774070 | 0 | 2023-01-17 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 2.0131 | 622544 | 853 | 2022-12-31 | LOW |
| Kumar (Amit) | Individual Investor | 1.4943 | 462100 | 0 | 2023-01-17 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9353 | 289238 | -2985 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.887 | 274289 | 3626 | 2022-12-31 | LOW |
| Long Focus Capital Management LLC | Hedge Fund | 0.5358 | 165701 | 0 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3302 | 102100 | 0 | 2022-12-31 | LOW |
| Baskies (Arnold M) | Individual Investor | 0.3234 | 100000 | 0 | 2023-01-17 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2297 | 71023 | 31115 | 2022-12-31 | MED |
| Raymond James & Associates, Inc. | Research Firm | 0.185 | 57217 | -3629 | 2022-12-31 | LOW |
| Newton Investment Management North America, LLC | Investment Advisor | 0.179 | 55350 | 0 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1777 | 54948 | 0 | 2022-12-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.1582 | 48925 | -714 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1549 | 47900 | -9300 | 2022-12-31 | HIGH |
| Citadel Advisors LLC | Hedge Fund | 0.1536 | 47506 | 27896 | 2022-12-31 | HIGH |
| Gottschalk (Emily) | Individual Investor | 0.1477 | 45665 | 0 | 2023-01-17 | LOW |
| BNY Mellon Asset Management | Investment Advisor | 0.1367 | 42268 | -238 | 2022-12-31 | LOW |
| Cambridge Investment Research Advisors, Inc. | Investment Advisor | 0.1297 | 40100 | 25100 | 2022-12-31 | LOW |
| Corecap Advisors Inc | Investment Advisor/Hedge Fund | 0.1171 | 36209 | -1177 | 2022-12-31 | MED |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Anixa Biosciences, Inc. Company profile
Sobre Anixa Biosciences Inc
Anixa Biosciences, Inc. es una empresa de biotecnología. La empresa está desarrollando terapias y vacunas centradas en la oncología y las enfermedades infecciosas. La empresa está desarrollando una tecnología de células T de receptores endocrinos quiméricos, una tecnología de células T de receptores de antígenos quiméricos (CAR-T) centrada en el tratamiento del cáncer de ovario, y candidatos a fármacos antivirales para el tratamiento del COVID-19 centrados en la inhibición de ciertas funciones de las proteínas virales del virus. También está desarrollando una vacuna contra el cáncer de mama triple negativo (TNBC), la forma letal de cáncer de mama, y una vacuna contra el cáncer de ovario. Su tecnología CAR-T puede utilizarse como tratamiento contra múltiples tipos de tumores sólidos. Los segmentos de la empresa incluyen las terapias CAR-T, las vacunas contra el cáncer, las terapias antivirales, las actividades de diagnóstico del cáncer y las actividades de licencia de patentes. Su filial Certainty Therapeutics, Inc. (Certainty), está desarrollando medicamentos de inmunoterapia contra el cáncer.
| Industry: | Biotechnology & Medical Research (NEC) |
3150 Almaden Expy Ste 250
SAN JOSE
CALIFORNIA 95118
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com